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ABSTRACT 
Patients with proliferative diabetic retinopathy (PDR) who are refractory to complete panretinal photocoagulation (PRP) 
have a high risk of severe vision loss. The aim of this study was to evaluate the effectiveness of single-dose intravitreal 
bevacizumab (IVB) after complete PRP in patients with refractory PDR. Patients with retinal neovascularization (NV) 
secondary to diabetes mellitus and refractory to complete PRP were enrolled in this study. All patients received a single 
dose of 1.25 mg IVB at 3 months after completing the PRP. Patients underwent complete ophthalmic evaluation and 
fluorescein angiography (FA) at baseline and 1 month after injection. The main outcome measure was a reduction in the 
areas of leakage (mm2) on FA. All patients were evaluated at baseline and on every visit at 1 day, 1 week, and 1 month 
after the injection. A total of 21 consecutive patients (32 eyes) with PDR completed this study. Thirteen (61.9%) patients 
were female. The mean ± standard deviation (SD) age was 64.1 ± 5.6 years. Complete and partial response of 
angiographic leakage of NV was noted in 7 (21.9%) and 18 (56.2%) of 32 eyes after a single IVB injection, respectively. No 
satisfactory response of retinal NV was observed in 7 eyes (21.9%) at 1 month after the injection. There was a significant 
difference in age between response groups (partial and complete; 61.9 ± 4.4 years) versus the no-satisfactory response 
group (67.7 ± 5.9 years) (P = 0.007). No significant ocular or systemic adverse events were observed. A single-dose of IVB 
could be associated with a satisfactory response of retinal NV, secondary to PDR, in patients who are refractory to 
complete PRP. 
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INTRODUCTION 
Diabetic retinopathy (DR) is characterized by the 
progressive development of well-defined morphological 
abnormalities in the retinal microvasculature [1, 2]. 
Proliferative diabetic retinopathy (PDR) is characterized 
by the formation of new retinal vessels, which may lead 
to severe vision loss. PDR occurs in response to the 
ischemia-mediated release of vascular endothelial 
growth factor (VEGF) into the vitreous cavity [3-5]. 
Although the current gold standard for the treatment of 
PDR is panretinal photocoagulation (PRP), not all patients 
have a complete response and, sometimes, the disease 
recurs [6, 7]. Patients with PDR who had a complete PRP 
procedure that did not result in regression or disruption 
of retinal new vessels have a high risk of severe vision 
loss [4, 7]. In cases of persistent new vessels in spite of 
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complete PRP, there is a risk of complications such as 
intravitreal hemorrhage. Because no evidence-based 
therapy is available for such complicated cases, 
vitrectomy is often the only option, which by itself 
increases the risk of an inflammatory and proliferative 
exacerbation [8, 9]. Intravitreal injections of several 
drugs in combination with PRP have been shown to 
achieve more favorable therapeutic outcomes than PRP 
alone, but none of these agents have been able to 
substitute the remarkable durability and effectiveness of 
PRP in preventing vision loss in PDR [8, 10]. One such 
drug is bevacizumab (Avastin®; Genentech Inc., San 
Francisco, CA, USA), a recombinant humanized 
monoclonal antibody that blocks angiogenesis by 
inhibiting VEGF-A [7, 11, 12]. Some studies showed that 
VEGF seems to be the major stimulus responsible for an 
increase in vasopermeability, cell proliferation, and 
angiogenesis in diabetic retinopathy [8, 13]. Bevacizumab 
was approved by the U.S. Food and Drug 
Administration (FDA) for certain metastatic cancers such 
as lung, breast, renal, and brain cancers [11]. Although 
not currently approved by the FDA for PDR, the injection 
of 1.25–2.5 mg of bevacizumab into the vitreous cavity 
has been performed without significant intraocular 
toxicity [14]. 
On the basis of data showing increased levels of VEGF in 
the vitreous cavity in patients with proliferative retinal 
diseases, new therapeutic strategies were designed. 
Nowadays, there are several clinical trials that provided 
evidence that intravitreally administered anti-VEGF drugs 
may induce a short-term regression of new vessels in 
vasoproliferative disease [7, 8, 12, 15, 16]. In this study, 
we evaluated the effect of single-dose intravitreal 
bevacizumab (IVB) in patients with refractory PDR after 
complete PRP. 
MATERIALS AND METHODS 
This prospective, uncontrolled, non-randomized clinical 
study included 32 eyes of 21 patients. The study was 
conducted at our outpatient department (Diabetic 
Retinopathy, Department of Ophthalmology, Medical 
University of Isfahan) at Feiz University Hospital, a 
tertiary ophthalmology referral center. The study 
protocol was approved by the institutional ethics 
committee of Isfahan University of Medical Sciences, 
Isfahan, Iran. All participants were informed in detail 
about the nature of off-label use of this drug and the 
possible risks of this study. Informed consent was 
obtained from each participant. Patients aged ≥25 years 
with refractory PDR and visual acuity of at least 20/200 
were enrolled in the study. Refractory PDR in our study 
was defined as persistent active NV despite complete 
PRP (minimum of 1200 laser spots) at 3 months or more 
after the PRP treatment had been completed [17]. The 
exclusion criteria were as follows: patients with a single 
eye; history of glaucoma; active ocular inflammation; 
history of prior vitreoretinal surgery; intraocular surgery 
(cataract, capsulotomy) within the last 3 months; severe 
lens opacity precluding fundus examination; known 
coagulation abnormalities or current use of anticoagulant 
medications other than aspirin; known allergies to any 
relevant drugs being used in this study; history of 
thromboembolic events including myocardial infarction 
or cerebral vascular accident; uncontrolled hypertension; 
evidence of external ocular infection; and pregnant or 
lactating female patients. 
Intravitreal Injections Protocol 
The intravitreal injection of bevacizumab (Avastin®) was 
performed under sterile conditions using topical 
tetracaine 0.5% (Anestocaine®, Sina Darou, Tehran, Iran), 
after which 1.25 mg (0.05 ml) of Avastin® were injected 
at 4 mm from the limbus using a 30-gauge needle. 
Immediately after the injection was completed, hand 
motion and finger counting were evaluated. 
Postoperatively, patients were instructed to use 
ciprofloxacin eye drops four times per day for 5 days. 
Slit-lamp biomicroscopic examination included IOP 
(Goldman tonometry); dilated fundus examination was 
performed at baseline and on every visit at 1 day, 1 
week, and 1 month after the injection. Before IVB, 
standard fluorescein angiography (FA) (Heidelberg 
Engineering, Heidelberg, Germany) was performed in all 
patients to demonstrate retinal neovascularization at 
baseline (3 months after the laser treatment). FA was 
performed at 1 month after injection. Patients were 
scheduled for follow-up examination at 1 day, 1 week, 
and 1 month after the injection. FA images were taken at 
time points between minute 2 and 3 after fluorescein 
injection. The areas of leakage were used to evaluate the 
effects of IVB. The main outcome measure was a 
reduction in the areas of leakage (mm
2
) on FA [18]. We 
defined a reduction in the areas of leakage of less than 
30% as a no-satisfactory response, from 30% to 80% as a 
partial response, and of more than 80% as a complete 
response. Possible ocular and systemic side effects of 
IVB, including changes in the IOP, were recorded on 
every visit. 
Statistical analysis of the data was performed using SPSS 
software (version 16.0 SPSS, Inc., Chicago, IL). Number 
and percentage were used to describe the qualitative 
data and mean ± standard deviation (SD) to describe the 
quantitative data. The Fisher’s exact test and 
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independent samples t-test were used to describe data. 
A P-value <0.05 was considered statistically significant. 
RESULTS 
A total of 21 consecutive patients (32 eyes) with PDR 
completed this study. PRP had been previously 
performed on all patients. Of the 21 patients, 13 (61.9%) 
were female. The mean age was 64.1 ± 5.6 years (age 
range: 55–75 years). Eight (38.8%) patients had a history 
of hypertension and 17 (81%) had type II diabetes 
mellitus. The detailed data and clinical outcomes of 
patients after IVB are presented in Table 1. 
 
Table 1: Clinical Outcomes after Intravitreal Injection of Bevacizumab 
 Complete response Partial response No satisfactory response 
Sex    
Male (n = 19) 3 (15.8) 12 (63.1) 4 (21.1) 
Female (n = 13) 4 (30.8) 6 (46.2) 3 (23.1) 
Diabetes    
IDDM (n = 7) 0 (0) 6 (85.7) 1 (14.3) 
NIDDM (n = 25) 7 (28.0) 12 (48.0) 6 (24.0) 
Age 63.9 ± 4.6 61.1 ± 4.1 67.7 ± 5.9 
IDDM: Insulin-dependent diabetes mellitus; NIDDM: Non-insulin-dependent diabetes mellitus; SD: standard deviation 
Data are presented as mean ± SD or No (%). 
 
Figure 1: Changes in Amount of Leakage after Intravitreal Bevacizumab Injection in a 55-year-old Man 
 
A: Persistent Active Retinal Neovascularization-associated Diabetes Mellitus in Standard Fluorescein Angiography (Areas of Leakage) despite Complete 
Panretinal Photocoagulation at 3 Months after the Treatment 
B: Reduction the Areas of Leakage (>80%) Found in the Standard Fluorescein Angiography after Single-dose Intravitreal Bevacizumab (Complete 
Response). 
C: Fundus Photograph of the same Patient after Single-dose of Intravitreal Bevacizumab. 
 
At the 1-month follow-up visit after IVB, 21.9% of the 
treated eyes showed complete response of retinal NV. 
No satisfactory response of retinal NV was observed in 7 
(21.9%) eyes 1 month after the injection. There was no 
significant different between sex and regression of 
retinal NV (P = 0.99 by Fisher’s exact test) and type of 
diabetes and regression of retinal NV (P = 0.99 by Fisher’s 
exact test). There was a significant difference in age 
between satisfactory groups (partial and complete 
groups) versus the no-satisfactory group (61.9 ± 4.4 years 
versus 67.7 ± 5.9 years, respectively; P = 0.007 by 
independent samples t-test). No systemic or local 
adverse events were observed after IVB. No procedure-
related complications (e.g., endophthalmitis, uveitis, or 
ocular toxicity) were observed. 
DISCUSSION 
Our study demonstrated that a single-dose IVB could be 
a promising adjuvant in the treatment of refractory PDR 
after complete PRP. Since the currently used treatment 
modality of PRP has its limitations, combined anti-VEGF 
(Avastin®) therapy in PRP resistance subjects appears as 
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an alternative or adjunctive therapeutic option for PDR. 
The potential complications of PRP include inevitable 
devastation of the healthy retina lying next to the 
photocoagulated area, unfortunate scotomas due to 
lateral dissipation, and great pain due vertical dissipation 
[17]. The healthy human retina contains little VEGF; 
however, patients with active PDR present elevated 
vitreous levels of VEGF [5]. Increased VEGF, triggered by 
hypoxia, is a key mediator of retinal NV and macular 
edema [5, 8, 19]. In pathological processes, the increase 
in VEGF results in a stimulus to vasodilation, an increase 
of vascular permeability, endothelial cell proliferation, 
and activation of metalloproteinases that lyse the 
extracellular matrix, leaving space for the growth of a 
new vessel. In PDR, VEGF acts synergistically with other 
growth factors but is a necessary and sufficient factor for 
the induction of retinal and iris neovascularization in 
experimental models [9, 20]. Therefore, inhibition of 
VEGF by IVB could theoretically provide a potential 
therapeutic advantage for NV in PDR. The effect of 
antiangiogenic anti-VEGF on PDR has been studied by 
several investigators [15, 21]. PRP is a destructive 
procedure, often painful, and may be associated with a 
decreased peripheral visual field and an increased risk of 
macular edema [9, 22]. The current study demonstrated 
the advantage of a single-dose IVB on the management 
of patients with PDR after PRP. Some authors have 
reported reperfused NV after the first IVB [15, 23], a 
phenomenon that may be attributed to an insufficient 
amount of bevacizumab. Arevalo et al. reported a dose-
dependent response in NV regression in PDR [24]. 
Although the reason for this dose-dependent response of 
the retinal neovasculature is unknown and the optimal 
dose and dosing sequence for IVB is still undetermined, 
Arevalo et al. demonstrated the 2.5 mg seems to be 
more effective than the 1.25 mg dose to induce complete 
NV regression [24]. The clinical explanations are that the 
effect of IVB on the retinal neovasculature may be 
affected with other pathologies such as choroidal 
neovascularization or macular edema or by a previous 
treatment. However, the real cause remains unknown. 
Yang et al. hypothesized that the factors influencing the 
recurrence of retinal NV after the first injection may 
include the larger area of the ischemic retina, absence of 
prior laser PRP, staging of preexisting retinal new vessels, 
and the inadequacy of subsequent laser PRP [25]. This 
finding was compatible with our study, considering 
ischemic status may contribute to treatment response. 
Therefore, a complete PRP may be necessary to sustain a 
steady outcome of a single dose of IVB in patients with 
resistant PDR. Previous studies have investigated the 
benefits of the combination of IVB and PRP [18, 26, 27]. 
In patients with PDR, the total area of actively leaking NV 
was significantly reduced in the PRP + IVB group 
compared with PRP alone [18]. Compatible with our 
study, Tonello et al. showed the adjuvant use of IVB in 
PRP for patients with high-risk PDR had a positive effect 
on the reduction of dye leakage in FA within a short 
period of time [18]. Although the exact mechanism is 
unknown, it may be due to an additional effect of IVB in 
the prevention of leakage and its associated vision-
threatening complications. Mason et al. observed a single 
IVB before standard PRP may be beneficial in preventing 
PRP-induced visual dysfunction [27]. In contrast to our 
study, Mason et al. used IVB before PRP. Nevertheless, 
they showed that combination of IVB and PRP had more 
benefits than PRP alone since none of the eyes in the 
combination of IVB and PRP had either worse vision or a 
significant increase in foveal thickness [27]. Consistent 
with a previous study, Cho et al. showed the adjuvant use 
of a single 1.25 mg/0.05 ml IVB in PRP for PDR had a 
significantly lower occurrence of complications [26]. 
Schmidinger et al. showed that repeated IVB is a 
promising method to control retinal new vessels in 
patients with refractory to PRP. In their study, the 
leakage area after repeated 1 mg IVB after panretinal 
PRP during the 6-month follow-up was significantly 
reduced [28]. Although the dose of 1.0 mg bevacizumab 
used in the study of Schmidinger et al. was lower than 
that used in our study, the extent of vessel regression 
was approximately the same [28]. This may be due to the 
multiple injections in their study versus a single injection 
in our study. The limitations of the present study include 
the fact that it had relatively small number of patients 
(yet sufficient for statistical purposes) and a short-term 
follow-up period. There was no control group of PDR 
refractory to PRP without IVB treatment and a long-term 
prospective study is needed to confirm the maintenance 
of therapeutic benefit suggested in this study. Although 
our study has several limitations, the importance of our 
study lies in observing the clinical effect of single-dose 
bevacizumab in the treatment of refractory PDR after 
complete PRP. Therefore, based on these results, single-
dose bevacizumab may be a promising, safe, and 
effective adjuvant treatment for refractory PDR after 
complete PRP. 
CONCLUSIONS 
The short-term results of our study suggest that single-
dose IVB is associated with a satisfactory response of 
retinal NV secondary to PDR in patients who are 
refractory to complete PRP. Although this treatment is 
unlikely to result in the permanent reduction of new 
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retinal vessels, it might be a useful strategy for refractory 
cases. 
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